01 1Cipla
01 1LAMIVUDINE USP
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2015-01-29
Pay. Date : 2015-01-22
DMF Number : 17535
Submission : 2004-07-19
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is LAMIVUDINE USP, with a corresponding US DMF Number 17535.
Remarkably, this DMF maintains an Active status since its submission on July 19, 2004, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 29, 2015, and payment made on January 22, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II
